EUVIMEDEUVIMED entdecken
Crossref

A Phase I Study Of The Combination Of TZT-1027 (Soblidotin) And Gemcitabine Administered On Day 1 And 8 Every Three Weeks To Patients With Advanced Or Metastatic Solid Tumors

The Internet Journal of Oncology · 2008

DOI: 10.5580/15d9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Internet Journal of Oncology, 2008.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

(2008). A Phase I Study Of The Combination Of TZT-1027 (Soblidotin) And Gemcitabine Administered On Day 1 And 8 Every Three Weeks To Patients With Advanced Or Metastatic Solid Tumors. The Internet Journal of Oncology. https://doi.org/10.5580/15d9

Vancouver

A Phase I Study Of The Combination Of TZT-1027 (Soblidotin) And Gemcitabine Administered On Day 1 And 8 Every Three Weeks To Patients With Advanced Or Metastatic Solid Tumors. The Internet Journal of Oncology. 2008. doi:10.5580/15d9

BibTeX
@article{euvimed2008,
  title = {A Phase I Study Of The Combination Of TZT-1027 (Soblidotin) And Gemcitabine Administered On Day 1 And 8 Every Three Weeks To Patients With Advanced Or Metastatic Solid Tumors},
  journal = {The Internet Journal of Oncology},
  year = {2008},
  doi = {10.5580/15d9}
}
Kostenlos starten →